Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European guideline for imaging of primary paediatric and adult osteosarcoma and Ewing sarcoma: systematic review and joint statement by the FOSTER consortium, Euro Ewing Consortium, European Society of Paediatric Radiology, and the European Association of Nuclear Medicine.

The Lancet. Oncology·2026
Same author

Molecular tumor board availability and organization in sarcoma referral centers in Italy: are we on the right track?

Frontiers in oncology·2026
Same author

Editorial: Precision therapeutics in rare cancers: targeting tumor microenvironment and biomarker-driven approaches.

Frontiers in immunology·2026
Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026
Same author

Critical appraisal of patient-reported and clinician-reported outcome measures assessing functional outcomes in lower extremity bone sarcoma patients-a COSMIN-based systematic review.

Journal of patient-reported outcomes·2026
Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026

Related Experiment Video

Updated: Jul 14, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma.

Stefano Ferrari1, Emanuela Palmerini

  • 1Chemotherapy Department, Istituto Ortopedico Rizzoli, Bologna, Italy. stefano.ferrari@ior.it

Current Opinion in Oncology
|June 5, 2007
PubMed
Summary

Current chemotherapy for osteosarcoma using four drugs offers a 70% survival rate, but dose increases don't help. Further research is needed for new strategies and to manage long-term side effects of chemotherapy.

More Related Videos

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice
03:11

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice

Published on: June 7, 2024

Related Experiment Videos

Last Updated: Jul 14, 2026

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice
03:11

Gavage Strategy for Decoction Formula of Traditional Chinese Medicine in Osteosarcoma Model Mice

Published on: June 7, 2024

Area of Science:

  • Oncology
  • Chemotherapy Research

Background:

  • Osteosarcoma treatment has relied on a standard four-drug regimen.
  • Recent research focuses on refining existing therapies and understanding long-term side effects.

Purpose of the Study:

  • To review recent developments in chemotherapy for osteosarcoma.
  • To emphasize prospective clinical trials and late effects of chemotherapy.

Main Methods:

  • Review of recent clinical research and prospective trials in osteosarcoma chemotherapy.
  • Evaluation of late chemotherapy-related side effects.

Main Results:

  • Dose-intensification of the standard four-drug therapy (methotrexate, cisplatin, doxorubicin, ifosfamide) does not improve prognosis.
  • Significant focus on evaluating cardiac, renal, and auditive toxicity, infertility, and secondary tumors.
  • Emerging research suggests potential roles for muramyl tripeptide-phosphatidilethanolamine and mTOR inhibitors.

Conclusions:

  • Patients under 40 with nonmetastatic extremity osteosarcoma have a 70% 5-year survival rate with the current regimen.
  • Dose intensification is not beneficial; novel strategies are necessary for improved outcomes.
  • Mandatory prolonged follow-up is crucial to monitor for late effects, secondary tumors, and late relapses.